Effect Of Gene Silencing PD-L1 On Proliferation,Invasion And Migration Of Intrahepatic Cholangiocarcinoma Cells

Objective:To investigate the effect of PD-L1 on proliferation,invasion and metastasis of intrahepatic cholangiocarcinoma(ICC)。Methods:Transfecting the effective PD-L1 gene si RAN interference fragment into human intrahepatic cholangiocarcinoma HCCC9810 cells,down-regulating the expression of PD-L1。1 Using fluorescent quantitative PCR to detect the expression of PD-L1 gene in transfected intrahepatic cholangiocarcinoma cells;2 Using Western Blotting method to detect the expression of PD-L1 protein in transfected intrahepatic cholangiocarcinoma cells;3 The effect of proliferation on the proliferation of intrahepatic cholangiocarcinoma cells was observed by MTT proliferation assay;4 The cell scratch test was used to detect the fusion rate at 0h,24 h and 36 h,and the Transwell chamber was used for invasion test to observe the migration and invasion ability of intrahepatic cholangiocarcinoma cells.Results:1 In the real-time PCR experiment,the PD-L1 gene expression level of the PD-L1 interference group was lower than that of the negative control group and the normal control group.2.In the Western Blootting experiment,the protein expression of PD-L1 in the PD-L1 interference group was lower than that in the negative control group and the normal control group.3.In the MTT proliferation experiment,the proliferation ability of the PD-L1 interference group was lower than that of the negative control group and the normal control group.4.In the migration and invasion experiments,the migration ability and invasion ability of the PD-L1 interference group were lower than those of the negative control group and the normal control group.Conclusions:1.After PD-L1 is down-regulated,the proliferation,migration and invasion ability of intrahepatic cholangiocarcinoma cells are reduced to some extent;2.PD-L1 may become a new gene target in immunotherapy of intrahepatic cholangiocarcinoma To provide a preliminary laboratory basis for the development of intrahepatic cholangiocarcinoma targeted anti-tumor drugs.